FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

GE Recalls Unstable Nuclear Medicine Devices

GE HealthCare recalls its Nuclear Medicine 600 and 800 Series systems after identifying an issue with two mechanisms that prevent uncontrolled detecto...

latest-news-card-1
Human Drugs

Drug R&D Cant Justify High Prices: Study

UK-based researchers say their analysis of drug company financial records doesnt support company claims that high drug prices are needed to support re...

latest-news-card-1
Human Drugs

Further FDA Opioid Crisis Strategies: Califf

FDA commissioner Robert Califf outlines ways the agency is taking additional steps as part of its response to the nations opioid crisis.

latest-news-card-1
Human Drugs

30 New Product-Specific Guidances Out

FDA releases a batch of 30 new and revised product-specific guidances to aid in the development of generic drugs.

latest-news-card-1
Human Drugs

Pfizer Says Talzenna Prostate Cancer Study Positive

Pfizer says FDA has granted priority review for its sNDA for Talzenna and Xtandi which showed positive results in a Phase 3 study for treating metasta...

latest-news-card-1
Human Drugs

FDA Approves BioVex BLA Supplement

FDA approves a BioVex BLA supplement to update the adverse drug reactions for its talimogene laherparepvec melanoma treatment.

Medical Devices

Merit Medical Breakthrough Status for Scout Device

FDA grants Merit Medical Systems a breakthrough device designation for its Scout MD Surgical Guidance System.

latest-news-card-1
FDA General

GAO Identifies FDA Gaps in IRB Oversight

The Government Accountability Office calls on FDA and the HHS Office of Human Research Protections to take steps to improve their oversight of institu...

latest-news-card-1
Human Drugs

FDA Pushed Into Accelerated Approval Pricing Model

HHS directs FDA to work with CMS Innovation Center to test a proposed model that would adjust Medicare payments for accelerated approval drugs to expe...

latest-news-card-1
Federal Register

Regulatory Review Period for Bayers Aliqopa

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Bayers Aliqopa (copanlisib dihydrochloride).